3 November 2026
Sidley Represents Hanmi Pharm and Green Cross Biopharma in Licensing Agreement With BioMarin
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Josh Hofheimer Lead | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Lauren Grau | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Sabrina Glavota | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Jonathan P. Trang | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Michael P. Alcan | Sidley | Not stated | Tax | Not stated |
| Sophie Arkusinski | Sidley | Not stated | Tax | Not stated |
| Dr. Idan Netser | Sidley | Not stated | Emerging Companies and Venture Capital | Not stated |
| Lauren Kitces | Sidley | Not stated | Privacy and Cybersecurity | Not stated |
| Tomoki Ishiara | Sidley | Not stated | M&A | Not stated |
| Trevor L. Wear | Sidley | Not stated | Healthcare | Not stated |
| Taylor Andelman | Sidley | Not stated | Healthcare | Not stated |
| Kelly Cho | Sidley | Not stated | Food, Drug and Medical Device | Not stated |
9 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 475m (US$475 million)
- What the figure measures
- Total transaction value
- Client
- Not stated
- Counterparties
- BioMarin Pharmaceutical Inc. (Other)